Suzhou Ribo生命科学在其RiboPepSTARTM平台上提供临床预科数据,显示在各种物种间向肾脏有效交付SiRNA,以及治疗肝脏以外疾病的潜力。 Suzhou Ribo Life Science to present preclinical data on its RiboPepSTAR™ platform, showing effective siRNA delivery to kidneys across species and potential for treating diseases beyond the liver.

Suzhou Ribo生命科学将在2026年3月19日RNA领导人欧洲会议上,在其RiboPepSTARTM平台上提供临床前期数据,展示SiRNA在各种物种(包括鼠类和非人类灵长类动物)中成功地向肾脏(包括鼠类和非人类灵长类动物)交付SiRNA,并在疾病模型中验证 mRNA的击倒。 Suzhou Ribo Life Science will present preclinical data on its RiboPepSTAR™ platform at the RNA Leaders Europe Conference on March 19, 2026, showcasing successful siRNA delivery to kidneys across species, including rodents and non-human primates, with mRNA knockdown validated in disease models. 该公司正在扩大范围,超越针对肝脏的治疗,开发心脏、脂肪组织、肌肉和中枢神经系统的候选方案,以扩大以SIRNA为基础的治疗应用。 The company is expanding beyond liver-targeted therapies, developing candidates for the heart, adipose tissue, muscle, and central nervous system to broaden siRNA-based treatment applications. 这遵循了其已建立的RiboGalSTARTM平台和正在进行的临床方案。 This follows its established RiboGalSTAR™ platform and ongoing clinical programs.